Ascletis Pharma Inc. (HKG: 1672), a biopharmaceutical company based in China, has announced positive interim results from a 12-week Phase II clinical study of its thyroid hormone receptor β (THRβ) agonist, ASC41, in patients with metabolic dysfunction-associated steatohepatitis (MSAH).
The randomized, double-blinded, placebo-controlled, and multi-center Phase II trial demonstrated significant outcomes in liver biopsy-proven MSAH patients who underwent 12 weeks of ASC41 treatment. The study showed an average relative decrease of 68.2% in liver fat content compared to baseline. ASC41 exhibited substantial reductions in liver fat, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and blood lipids in MSAH patients, presenting with clinical significance and a favorable safety and tolerability profile.
ASC41 is a liver disease-targeted small-molecule drug that can be converted into its active metabolite, ASC41-A. It exhibits high selectivity for THRβ and is protected by patents in the US for its tablet formulation.- Flcube.com
